Amna Ibrahim

6.4k citations
58 papers · 2.9k · 1 hit paper · h-index 26

Impact in

Papers in

  • Oncology 27
    • Cancer Treatment and Pharmacology 11
    • HER2/EGFR in Cancer Research 9
    • Cancer Immunotherapy and Biomarkers 7
  • Pulmonary and Respiratory Medicine 23
    • Renal cell carcinoma treatment 7
    • Prostate Cancer Treatment and Research 7
Co-authors
Richard Pazdur (42 shared papers)Rajeshwari Sridhara (25 shared papers)Shenghui Tang (33 shared papers)Robert Justice (8 shared papers)Julia A. Beaver (25 shared papers)Martin H. Cohen (4 shared papers)Kirsten B. Goldberg (16 shared papers)Laleh Amiri‐Kordestani (16 shared papers)
Journals
Clinical Cancer Research (14 papers)Journal of Clinical Oncology (14 papers)The Oncologist (8 papers)Clinical Pharmacology & Therapeutics (2 papers)Annals of Oncology (2 papers)
Partner nations
United StatesEgyptSudan

In The Last Decade

Amna Ibrahim

55 papers receiving 2.9k citations

Amna Ibrahim's Hit Papers

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer 2022 · 127 citations
1270+1+2Years since publication4080120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2022 Clinical Cancer Research

Peers

Amna Ibrahim
Comparison fields: 5 of 105
  • Oncology 1.7k
  • Pulmonary and Respiratory Medicine 1.1k
  • Cancer Research 457
  • Radiology, Nuclear Medicine and Imaging 615
  • Genetics 207
Replace Laleh Amiri‐Kordestani with:
Laleh Amiri‐Kordestani United States
Richard A. Messmann United States
Binghe Xu China
Stephen D. Rubin United States
Neville Davidson United Kingdom
Zefei Jiang China
Steven Stein United States
Susan Galbraith United States
Alvaro Moreno‐Aspitia United States
Mauricio Burotto United States
Amna Ibrahim relative to Laleh Amiri‐Kordestani United States Laleh Amiri‐Kordestani's profile →
Citations per field
00.5×1.5×
Laleh Amiri‐Kordestani · 1×
Citations per year

Countries citing papers authored by Amna Ibrahim

Since Specialization
Citations

This map shows the geographic impact of Amna Ibrahim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amna Ibrahim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amna Ibrahim more than expected).

Fields of papers citing papers by Amna Ibrahim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amna Ibrahim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amna Ibrahim. The network helps show where Amna Ibrahim may publish in the future.

Co-authors

The 25 scholars most cited alongside Amna Ibrahim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Amna Ibrahim Line = papers co-authored together Amna Ibrahim links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 58 papers — load more, or switch the sort, to bring in the rest.

#Work
1
FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2
The Oncologist ·Qin Ryan, Amna Ibrahim, Martin H. Cohen, John R. Johnson, Chia‐Wen Ko, Rajeshwari Sridhara, Robert Justice, Richard Pazdur
2008236
2
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
Journal of Clinical Oncology ·V. Ellen Maher, Laura L. Fernandes, Chana Weinstock, Shenghui Tang, Sundeep Agarwal, Michael H. Brave, Yang-Min Ning, Harpreet Singh, Daniel L. Suzman, James Xu, Kirsten B. Goldberg, Rajeshwari Sridhara, Amna Ibrahim, Marc R. Theoret, Julia A. Beaver, Richard Pazdur
2019231
3
FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
The Oncologist ·Virginia E. Kwitkowski, Tatiana M. Prowell, Amna Ibrahim, Ann T. Farrell, Robert Justice, Shan Sun Mitchell, Rajeshwari Sridhara, Richard Pazdur
2010196
4
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
The Lancet Oncology ·Jennifer Gao, Joyce Cheng, Erik Bloomquist, Jacquelyn Sanchez, Suparna Wedam, Harpreet Singh, Laleh Amiri‐Kordestani, Amna Ibrahim, Rajeshwari Sridhara, Kirsten B. Goldberg, Marc R. Theoret, Paul G. Kluetz, Gideon M. Blumenthal, Richard Pazdur, Julia A. Beaver, Tatiana M. Prowell
2019194
5
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
PubMed ·Amna Ibrahim, Nancy S. Scher, Grant Williams, Rajeshwari Sridhara, Ning Li, Gang Chen, John Leighton, Brian Booth, Jogarao Gobburu, Atiqur Rahman, Yung Hsieh, Rebecca Wood, Debra Vause, Richard Pazdur
2003157
6
FDA Drug Approval Summaries: Oxaliplatin
The Oncologist ·Amna Ibrahim, Steven Hirschfeld, Martin H. Cohen, Donna Griebel, Grant A. Williams, Richard Pazdur
2004140
7
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy
The Oncologist ·Daniel L. Suzman, Sundeep Agrawal, Yang-Min Ning, V. Ellen Maher, Laura L. Fernandes, Stella Karuri, Shenghui Tang, Rajeshwari Sridhara, Jason Schroeder, Kirsten B. Goldberg, Amna Ibrahim, Amy E. McKee, Richard Pazdur, Julia A. Beaver
2018138
8
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
Clinical Cancer Research ·Elaine Chang, Chana Weinstock, Lijun Zhang, Rosane Charlab, Sarah E. Dorff, Yutao Gong, Vicky Hsu, Fang Li, Tiffany K. Ricks, Pengfei Song, Shenghui Tang, Peter Waldron, Jingyu Yu, Eias Zahalka, Kirsten B. Goldberg, Richard Pazdur, Marc R. Theoret, Amna Ibrahim, Julia A. Beaver
2020135
9
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer
Clinical Cancer Research ·Jaleh Fallah, Sundeep Agrawal, Haley Gittleman, Mallorie H. Fiero, Sriram Subramaniam, Christy S. John, Wei Chen, Tiffany K. Ricks, Gang Niu, Anthony F. Fotenos, Min Wang, Kelly Chiang, William F. Pierce, Daniel L. Suzman, Shenghui Tang, Richard Pazdur, Laleh Amiri‐Kordestani, Amna Ibrahim, Paul G. Kluetz
Hit paper breakdown →		2022127
10
Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary
Clinical Cancer Research ·Paul G. Kluetz, William F. Pierce, V. Ellen Maher, Hui Zhang, Shenghui Tang, Pengfei Song, Qi Liu, Martin T. Haber, Eldon E. Leutzinger, Ali Al‐Hakim, Wei Chen, Todd R. Palmby, Elleni Alebachew, Rajeshwari Sridhara, Amna Ibrahim, Robert Justice, Richard Pazdur
2013125
11
First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer
Clinical Cancer Research ·Laleh Amiri‐Kordestani, Suparna Wedam, Lijun Zhang, Shenghui Tang, Amy Tilley, Amna Ibrahim, Robert Justice, Richard Pazdur, Patricia Cortazar
2014114
12
First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer
Clinical Cancer Research ·Gideon M. Blumenthal, Nancy S. Scher, Patricia Cortazar, Somesh Chattopadhyay, Shenghui Tang, Pengfei Song, Qi Liu, Kimberly Ringgold, Anne M. Pilaro, Amy Tilley, Kathryn E. King, Laurie Graham, Barbara L. Rellahan, Wendy C. Weinberg, Bo Chi, Colleen J. Thomas, P. E. Hughes, Amna Ibrahim, Robert Justice, Richard Pazdur
201389
13
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Clinical Cancer Research ·Anand Shah, Erik Bloomquist, Shenghui Tang, Wentao Fu, Youwei Bi, Qi Liu, Jingyu Yu, Ping Zhao, Todd R. Palmby, Kirsten B. Goldberg, C.J. George Chang, Paresma Patel, Elleni Alebachew, Amy Tilley, William F. Pierce, Amna Ibrahim, Gideon M. Blumenthal, Rajeshwari Sridhara, Julia A. Beaver, Richard Pazdur
201888
14
Drug Approval Summaries: Arsenic Trioxide, Tamoxifen Citrate, Anastrazole, Paclitaxel, Bexarotene
The Oncologist ·Martin H. Cohen, Steven Hirschfeld, Susan Flamm Honig, Amna Ibrahim, John R. Johnson, James J. O’Leary, Robert M. White, Grant A. Williams, Richard Pazdur
200187
15
External control arms in oncology: current use and future directions
Annals of Oncology ·Pallavi S. Mishra‐Kalyani, L. Amiri Kordestani, Donna R. Rivera, Harpreet Singh, Amna Ibrahim, R. Angelo DeClaro, Yuan Li Shen, Shenghui Tang, R. Sridhara, Paul G. Kluetz, John Concato, Richard Pazdur, Julia A. Beaver
202278
16
FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis
The Oncologist ·James Xu, V. Ellen Maher, Lijun Zhang, Shenghui Tang, Rajeshwari Sridhara, Amna Ibrahim, Geoffrey Kim, Richard Pazdur
201777
17
U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer
Clinical Cancer Research ·Harpreet Singh, Amanda J. Walker, Laleh Amiri‐Kordestani, Joyce Cheng, Shenghui Tang, Pamela Balcazar, Kimberly Barnett-Ringgold, Todd R. Palmby, Xianhua Cao, Nan Zheng, Qi Liu, Jingyu Yu, William F. Pierce, Selena Daniels, Rajeshwari Sridhara, Amna Ibrahim, Paul G. Kluetz, Gideon M. Blumenthal, Julia A. Beaver, Richard Pazdur
201875
18
FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer
Clinical Cancer Research ·Suparna Wedam, Lola A. Fashoyin‐Aje, Xin Gao, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Kirsten B. Goldberg, Bellinda L. King‐Kallimanis, Marc R. Theoret, Amna Ibrahim, Laleh Amiri‐Kordestani, Richard Pazdur, Julia A. Beaver
202065
19
The Role of SN‐38 Exposure, UGT1A1*28 Polymorphism, and Baseline Bilirubin Level in Predicting Severe Irinotecan Toxicity
The Journal of Clinical Pharmacology ·Roshni Ramchandani, Yaning Wang, Brian Booth, Amna Ibrahim, John R. Johnson, Atiqur Rahman, Mehul Mehta, Federico Innocenti, Mark J. Ratain, Jogarao Gobburu
200663
20
Exposure–Response Relationship of T-DM1: Insight Into Dose Optimization for Patients With HER2-Positive Metastatic Breast Cancer
Clinical Pharmacology & Therapeutics ·J Wang, Pengfei Song, Sarah J. Schrieber, Q Liu, Qiang Xu, Gideon M. Blumenthal, L. Amiri Kordestani, Patricia Cortazar, Amna Ibrahim, Robert Justice, Y Wang, Shenghui Tang, B Booth, Nitin Mehrotra, Atiqur Rahman
201451

About Amna Ibrahim

Amna Ibrahim is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Surgery and Radiology, Nuclear Medicine and Imaging, having authored 58 papers that have together received 2.9k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (11 papers), Cancer Genomics and Diagnostics (10 papers), HER2/EGFR in Cancer Research (9 papers), Bladder and Urothelial Cancer Treatments (8 papers), Radiopharmaceutical Chemistry and Applications (8 papers), Renal cell carcinoma treatment (7 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Prostate Cancer Treatment and Research (7 papers). The work is most often cited by research in Oncology (1.7k citations), Pulmonary and Respiratory Medicine (1.1k citations), Cancer Research (457 citations), Radiology, Nuclear Medicine and Imaging (615 citations) and Genetics (207 citations). Amna Ibrahim has collaborated with scholars based in United States, Egypt and Sudan. Frequent co-authors include Richard Pazdur, Rajeshwari Sridhara, Shenghui Tang, Robert Justice, Julia A. Beaver, Martin H. Cohen, Kirsten B. Goldberg, Laleh Amiri‐Kordestani, V. Ellen Maher and Paul G. Kluetz. Their work appears in journals such as Clinical Cancer Research, Journal of Clinical Oncology, The Oncologist, Clinical Pharmacology & Therapeutics and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laleh Amiri‐KordestaniBreakdown of academic impact, for papers by Richard A. MessmannBreakdown of academic impact, for papers by Binghe XuBreakdown of academic impact, for papers by Stephen D. RubinBreakdown of academic impact, for papers by Neville DavidsonBreakdown of academic impact, for papers by Zefei JiangBreakdown of academic impact, for papers by Steven SteinBreakdown of academic impact, for papers by Susan GalbraithBreakdown of academic impact, for papers by Alvaro Moreno‐AspitiaBreakdown of academic impact, for papers by Mauricio Burotto